



Ed Fryer

request-646128-3484f6e2@whatdotheyknow.com

12 March 2020

Our Ref: RFI 33567

Dear Mr Fryer

Freedom of Information Act 2000

Information in relation to the use of Entyvio for the treatment of Ulcerative colitis and Crohn's disease

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now partially completed its search for information relating to above the which you requested on 13 February 2020.

A response to questions 2 and 4 raised has been provided by the Hospital Services Directorate and is attached in Appendix A. A response to questions 1 and 3 will be provided as soon as possible.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

pp

Jane McCormick
Information Governance Assistant

Q2. Of these patients how many were treated with Entyvio (vedolizumab)?

A2. 43 patients with Ulcerative Colitis have been treated with vedolizumab in last 12 months.

Q4. Of the patients how many were treated with Entyvio (vedolizumab)?

A4. 37 patients with Crohn's disease have been treated with vedolizumab in last 12 months.